share_log

MedMira Announces the Hire of Vice President of Business Development

MedMira Announces the Hire of Vice President of Business Development

MedMira宣佈聘請業務發展副總裁
Accesswire ·  05/01 10:00

HALIFAX, NS / ACCESSWIRE / April 30, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to announce the expansion of their commercialisation team by welcoming Ms. Rene Bell to the position of Vice President of Business Development.

新澤西州哈利法克斯/ACCESSWIRE/2024年4月30日/今天,MedMira Inc.(MedMIRA)(多倫多證券交易所股票代碼:MIR)很高興地宣佈擴大其商業化團隊,歡迎雷內·貝爾女士擔任業務發展副總裁一職。

Ms. Bell brings over 20 years of Business Development and Sales experience in the United States and international markets. Her extensive knowledge of the US healthcare market, coupled with her deep understanding of technical intricacies, positions her as a key asset in MedMira's growth strategy. Her past contributions at companies such as Akers Bioscience have been pivotal in forging significant partnerships and driving sales. In her new role, Ms. Bell will focus on increasing direct sales in the short term and establishing additional partnerships with new distributors. Additionally, she will spearhead the formation of a dedicated US-based team to support existing partners like VWR, Cardinal Health, Medline and additional new partners, thereby maximizing sales opportunities.

貝爾女士在美國和國際市場擁有超過20年的業務開發和銷售經驗。她對美國醫療保健市場的廣泛了解,加上對技術複雜性的深刻理解,使她成爲MedMira增長戰略中的關鍵資產。她過去在Akers Bioscience等公司所做的貢獻對於建立重要的合作伙伴關係和推動銷售至關重要。在新的職位上,貝爾女士將專注於在短期內增加直接銷售,並與新的分銷商建立更多合作伙伴關係。此外,她將帶頭組建一支專門的美國團隊,爲VWR、Cardinal Health、Medline等現有合作伙伴和其他新合作伙伴提供支持,從而最大限度地提高銷售機會。

"We truly believe that our technology and products are one of the best in the market. While our technical capabilities have been proven to be of the highest quality, we require to expand our talents to market MedMira's products in a fast and sustainable way. Rene has an abundance of such skills and her past work is a testament to her expertise." said Hermes Chan, CEO of MedMira. "We know that she will leverage her expertise to support MedMira's growth strategy and significantly contribute to our sales and with it substantially increase our revenues in both short-term and long-term."

“我們堅信我們的技術和產品是市場上最好的技術和產品之一。儘管我們的技術能力已被證明是最高質量的,但我們需要擴大我們的人才,以快速和可持續的方式推銷MedMira的產品。Rene擁有豐富的此類技能,她過去的工作證明了她的專業知識。” MedMira首席執行官Hermes Chan說。“我們知道她將利用自己的專業知識來支持MedMira的增長戰略,爲我們的銷售做出重大貢獻,從而大幅增加我們的短期和長期收入。”

Ms. Bell's appointment marks a significant milestone in MedMira's 2024 strategy, which aims to aggressively expand its presence in the US market. With a focus on its current G4 HIV and Miriad product lines, as well as upcoming innovations like the G4 CLIA waived product line, MedMira is poised for continued success under Ms. Bell's guidance.

貝爾女士的任命標誌着MedMira2024年戰略的一個重要里程碑,該戰略旨在積極擴大其在美國市場的影響力。MedMira專注於其目前的G4 HIV和Miriad產品線,以及即將推出的創新,例如G4 CLIA豁免的產品線,有望在貝爾女士的指導下繼續取得成功。

About MedMira

關於 MedMira

MedMira is a leading developer and manufacturer of Rapid Vertical Flow diagnostics. The Company's tests provide hospitals, labs, clinics and individuals with instant disease diagnosis, such as HIV, Syphilis, Hepatitis, and SARS-CoV-2, in just three easy steps. The Company's tests are sold globally under the REVEAL, REVEALCOVID-19,Multiplo and Miriad brands. Based on its patented Rapid Vertical Flow Technology, MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit medmira.com. Follow us on Twitter and LinkedIn.

MedMira 是 Rapid Vertical Flow 的領先開發商和製造商 診斷。該公司的測試僅需三個簡單步驟,即可爲醫院、實驗室、診所和個人提供即時疾病診斷,例如艾滋病毒、梅毒、肝炎和SARS-CoV-2。該公司的測試通過REVEAL在全球銷售,REVEALCOVID-19,Multilo 和 Miriad 品牌。基於其獲得專利的 “快速垂直流” 科技,MedMira的HIV快速檢測是世界上唯一獲得加拿大,美國,中國和歐盟監管部門批准的檢測。MedMira的公司辦公室和製造設施位於加拿大新斯科舍省哈利法克斯。欲了解更多信息,請訪問 medmira.com。關注我們 推特領英

This news release contains forward‐looking statements, which involve risk and uncertainties and reflect the Company's current expectation regarding future events, including statements regarding possible regulatory approval, product launch, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

本新聞稿包含前瞻性陳述,這些陳述涉及風險和不確定性,反映了公司當前對未來事件的預期,包括有關可能的監管批准、產品發佈、未來增長和新商機的聲明。實際事件可能與本文預測的有重大差異,取決於多種因素,包括但不限於不斷變化的市場狀況、成功及時完成臨床研究、與監管審批程序相關的不確定性、公司聯盟的建立以及公司季度文件中不時詳述的其他風險。

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

多倫多證券交易所風險投資交易所及其監管服務提供商(該術語在多倫多證券交易所風險交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

MedMira Contact:

MedMira 聯繫人:

Markus Meile
Chief Financial Officer
MedMira Inc.
ir@medmira.com

Markus Meile
首席財務官
MedMira Inc.
ir@medmira.com

SOURCE: MedMira Inc.

資料來源:MedMira Inc.


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論